The Latest Breaking News from Tilray Brands

Tilray Brands Inc (NASDAQ:TLRY) stock is trending across social media Thursday, despite a lack of fresh company-specific news for the session. The cannabis and consumer brands company made several strategic moves in June that could be fueling the current interest.

Tilray reported a positive update for its chemo-related drug.

Canadian cannabis leader Tilray Brands (TLRY) is bolstering its portfolio through expansions and partnerships. However, the company’s recent $150 million offering of senior notes put pressure on its stock price. Would it be wise to buy the stock now? Let’s look at its financial metrics to answer that….

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

Mad Money host Jim Cramer said last week during a Lightning Round segment that now is a good time to invest in Tilray.

Canadian marijuana giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) reported Friday financial results for the first fiscal quarter ended August 31, 2022, with net revenue of $153.2 million, which compares to revenue of $168.02 million for the same period last year.

 

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) net revenue grew 8% to $153.3 million during the fourth quarter 2022, from $142.2 million in the prior year quarter.

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) has closed its acquisition from HT Investments MA LLC (“HTI”) of the secured convertible note issued by HEXO Corp. (NASDAQ: HEXO